The G-BA specifies QA requirements for cell and gene therapies in Germany
In the previous assessments of Kymriah, Yescarta, Tecartus, and Zolgensma, the G-BA had defined specific QA requirements for the use of these
Category: News and updates
G-BA assessment of orphan drug gene therapies, Zolgensma and Libmeldy
The gene therapies Zolgensma and Libmeldy, both, are targeting very rare, severe, genetic diseases in children. The G-BA has now assessed the
Reimbursement price and discounts – Drug prices in Germany
You might be familiar with the price negotiations to derive the reimbursement price, but this does not always reflect the final, real-world
Another reimbursement restriction in Germany
Most medicines are reimbursed at 100% from the day of launch in Germany, i.e. coverage by SHI funds is granted with the marketing authorization
Why did the G-BA assess Trimbow now?
Trimbow was launched onto the German market in 2017. So why did the G-BA assess its benefit now? You likely know that